Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Robert Hershberg Sells 25,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the completion of the transaction, the director owned 162,156 shares in the company, valued at approximately $810,780. This trade represents a 13.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded down $0.36 during trading hours on Wednesday, hitting $4.27. The company had a trading volume of 40,600,630 shares, compared to its average volume of 19,026,078. The firm has a 50-day moving average of $3.50 and a 200 day moving average of $3.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The firm has a market cap of $2.29 billion, a PE ratio of -4.11 and a beta of 1.04. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The firm had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same quarter in the prior year, the firm earned ($0.41) EPS. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -0.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RXRX shares. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.06.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $23,473,000. First Trust Advisors LP grew its holdings in Recursion Pharmaceuticals by 15.2% during the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after acquiring an additional 344,035 shares during the last quarter. Bank of America Corp DE increased its position in Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after acquiring an additional 384,486 shares during the period. Renaissance Technologies LLC acquired a new position in Recursion Pharmaceuticals in the 1st quarter valued at approximately $7,370,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Recursion Pharmaceuticals by 29.3% during the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after acquiring an additional 331,048 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.